Clinical Trial Update: A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the anti-TNF agent golimumab (SIMPONI) to arrest beta-cell loss in Type 1 diabetes; the study has completed and results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: COMPLETED | Results posted: 2022-07-14